A 2-part, multi-center, open-label trial to study safety, tolerability and pharmacodynamic (PD) effects of siponimod in healthy cytochrome P450(CYP)2C9 poor metabolizers (PM) compared to extensive metabolizers (EM) at single and multiple doses
Latest Information Update: 06 May 2016
At a glance
- Drugs Siponimod (Primary)
- Indications Dermatomyositis
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 06 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology